Fig. 1 · Structure

Documents & Downloads

Honokiol

Cat. No. A10453 CAS 35354-74-6

Antiangiogenic and Antitumor Agent

Honokiol is a lignan present in the cones, bark, and leaves of Magnolia grandiflora that has shown pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Honokiol reduced TNF-α-induced NF-κB p65 nuclear localization and preserved IκBα in mouse cerebral endothelial cells. The MG132 control did not establish significant inhibition of IκBα phosphorylation, so these findings support pathway modulation without defining honokiol as a direct IKK inhibitor. [1]

Honokiol potentiated recombinant GABA-A receptor currents in a subunit- and agonist-dependent manner. Modulation EC50 values were 1.17 ± 0.2 μM at α1β3γ2 and 3.80 ± 0.41 μM at α1β3δ receptors under low-GABA conditions. At 1 mM GABA, 10 μM honokiol did not increase the α1β3γ2 peak response. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Akt-phosphorylation
MEK

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 30.5 μM Antiproliferative activity against human A2780 cells after 24 hrs by MTT assay [PMID: 31278004]
A2780 IC50 30.5 μM Antiproliferative activity against cisplatin-sensitive human A2780 cells by MTT assay [PMID: 19589678]
A2780 IC50 31.58 μM Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 32996316]
A2780 IC50 41.2 μM Antiproliferative activity against cisplatin-resistant human A2780 cells by MTT assay [PMID: 19589678]
A549 IC50 > 5 μg/mL Cytotoxicity against human A549 cells by MTT assay [PMID: 17918910]
A549 IC50 12.51 μM Cytotoxicity against human A549 cells after 24 hrs by MTS assay [PMID: 22533983]
A549 IC50 29.7 μM Antiproliferative activity against human A549 cells by MTT assay [PMID: 31278004]
A549 IC50 34.1 μM Antiproliferative activity against human A549 cells after 24 hrs by MTT assay [PMID: 31278004]
A549 IC50 35 μM Antiproliferative activity against human A549 cells after 24 hrs by MTT assay [PMID: 21853991]
A549 IC50 35 μM Antiproliferative activity against human A549 cells by MTT assay [PMID: 19589678]
A549 IC50 35.31 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 30006164]
A549 IC50 35.41 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 31278004]
A549 IC50 38.04 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 32996316]
A549 IC50 7.75 μM Cytotoxicity against human A549 cells after 72 hrs by MTS assay [PMID: 22533983]
BV-2 IC50 17 μM Anti-inflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay [PMID: 30472026]
CHO EC50 > 10 μM Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 5 mins by cAMP-competition binding assay [PMID: 24900561]
CNE2Z IC50 31.27 μM Antiproliferative activity against human CNE2Z cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 31831382]
HCC827 IC50 33.88 μM Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay [PMID: 30006164]
HCT-116 IC50 19.05 μM Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay [PMID: 31278004]
HCT-116 IC50 47.65 μM Antitumor activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay [PMID: 36332549]

20 records · Scroll to view more

In Vitro Studies

In a mouse endothelial-cell/human-neutrophil adhesion assay, 1–10 μM honokiol pretreatment reduced TNF-α-induced adhesion. Endothelial viability was unchanged in the separate 6 h control. Effects on neutrophils may also contribute to the adhesion result. [1]

TNF-α-induced neutrophil adhesion to cerebral endothelial cells

Cell-based study · Mouse bEnd.3 cerebral endothelial cells with human neutrophils from healthy volunteers [1]

Honokiol decreased neutrophil adhesion following TNF-α stimulation. A separate viability control showed no loss of endothelial viability under the tested 6 h condition. Direct effects on neutrophils may contribute.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Adherent human neutrophils on bEnd.3 monolayersqualitative result Decreased adhesion after honokiol pretreatment relative to TNF-α alone; no exact percentage extracted[1]
Endothelial viability with TNF-αviability control No alteration reported at 1, 3 or 10 μM honokiol in the 6 h TNF-α condition[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3 and 10 μM
Exposure duration
30 min pretreatment; TNF-α for 3 h, then neutrophil adhesion for 30 min; viability control: TNF-α for 6 h
Method
Microscopy-based adhesion and WST-1 viability assays
Vehicle
0.1% DMSO
Co-treatment
TNF-α 10 ng/ml inflammatory stimulus; compared with DMSO and TNF-α alone
Reported limits
Donor count is not specified for this selected experiment; n=5 experiments performed in duplicate is not a donor count.
Methods and source locations

Compound reported in the paper: Honokiol; Compound label in the paper: honokiol

Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.

Fig. 1A,C–E; Results: Honokiol suppressed TNF-α-induced neutrophil adhesion; Methods: material identity, cell culture, neutrophil adhesion, viability, statistics

Adherent human neutrophils on bEnd.3 monolayers: DiI-labelled neutrophil adhesion microscopy; mean ± SEM from 5 experiments in duplicate — Fig. 1C,D and caption; corresponding Results

Endothelial viability with TNF-α: WST-1; mean ± SEM from 5 experiments in duplicate — Fig. 1E and caption; Methods: Cell viability assay

IκBα preservation and reduced NF-κB nuclear translocation

Cell-based study · Mouse bEnd.3 cerebral endothelial cells [1]

Honokiol preserved IκBα and reduced TNF-α-induced p65 nuclear localization. MG132 controls did not show significant suppression of IκBα phosphorylation by honokiol. GABA-A antagonist SR95531 did not reverse IκBα preservation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNF-α-induced p65 localization and IκBα losspathway response Reduced nuclear p65 localization; reduced IκBα degradation at 10 and 15 min[1]
IκBα phosphorylation and GABA-A dependence controlslimiting controls With MG132, phosphorylation suppression was not statistically significant; SR95531 did not reverse honokiol-mediated preservation of IκBα[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 μM
Exposure duration
30 min pretreatment; TNF-α for 15 min in microscopy; 5–30 min in immunoblot time course
Method
Immunofluorescence/confocal microscopy and tubulin-normalized immunoblotting
Vehicle
0.1% DMSO
Co-treatment
TNF-α 10 ng/ml; mechanistic controls: MG132 5 μM for 1 h, or SR95531 20 μM for 30 min; muscimol 100 μM comparator
Reported limits
No biochemical affinity, target selectivity or IC50 established by these experiments.
Methods and source locations

Compound reported in the paper: Honokiol; Compound label in the paper: honokiol

Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.

Figs. 3A,B and 4A–E; corresponding Results; Methods: immunofluorescence, immunoblot, material identity, statistics

TNF-α-induced p65 localization and IκBα loss: Microscopy (Fig. 3) and tubulin-normalized immunoblot time course (Fig. 4A,B) — Figs. 3A,B and 4A,B; Results: Honokiol prevented NF-κB nuclear translocation

IκBα phosphorylation and GABA-A dependence controls: Immunoblotting; 3 independent experiments, mean ± SEM — Fig. 4C–E and corresponding Results

Subunit- and agonist-dependent GABA-A receptor potentiation

Cell-based study · HEK-293T cells expressing recombinant α1β3γ2 or α1β3δ GABA-A receptors [2]

Honokiol potentiated responses to low GABA concentrations. δ-containing receptors had lower apparent potency but greater maximal response than γ2-containing receptors. At saturating GABA, honokiol did not increase the γ2 receptor peak response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Potentiation of response to 1 μM GABA at α1β3γ2 receptorsEC50 1.17 ± 0.2 μM (n=3 cells)[2]
Potentiation of response to 0.3 μM GABA at α1β3δ receptorsEC50 3.80 ± 0.41 μM (n=5 cells)[2]
Peak response to 1 mM GABA with 10 μM honokiolagonist-dependent limit No peak increase at α1β3γ2; nearly doubled peak response at α1β3δ (n=5 cells per honokiol group)[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–30 μM for concentration-response curves; 10 μM for saturating-GABA control
Exposure duration
5 s co-applications
Method
Whole-cell voltage clamp at −50 mV
Vehicle
DMSO ≤0.01%
Co-treatment
GABA 1 μM for α1β3γ2 and 0.3 μM for α1β3δ; saturating control: GABA 1 mM. Magnolol was a separate comparator.
Reported limits
Potencies are assay-dependent modulation EC50 values, not binding affinities or inhibitory IC50 values.
Methods and source locations

Compound reported in the paper: Honokiol; Compound label in the paper: honokiol

Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.

Methods 2.2 and 2.4; Results 3.2–3.3; Figs. 2–3 and captions

Potentiation of response to 1 μM GABA at α1β3γ2 receptors: Whole-cell concentration-response fit; response relative to GABA alone — Results 3.2; Fig. 2A,B and caption

Potentiation of response to 0.3 μM GABA at α1β3δ receptors: Whole-cell concentration-response fit; response relative to GABA alone — Results 3.2; Fig. 2A,B and caption

Peak response to 1 mM GABA with 10 μM honokiol: Whole-cell recordings; Fig. 3B mean ± SEM; no exact percentage read from bars — Results 3.3; Fig. 3A,B and caption

In Vivo Studies

In an isoproterenol-induced mouse cardiac hypertrophy model, honokiol at 0.2 mg/kg/day intraperitoneally reduced heart-weight/body-weight ratio and fibrosis in wild-type mice. These benefits were not significant in SIRT3-knockout mice, supporting a role for SIRT3 in this model. [3]

SIRT3 dependence in isoproterenol-induced cardiac hypertrophy

Animal study · Adult wild-type and SIRT3-knockout mice subjected to isoproterenol-induced cardiac hypertrophy [3]

Honokiol reduced heart-weight/body-weight ratio and interstitial fibrosis in wild-type mice, whereas the corresponding ISO versus ISO plus honokiol comparisons were not significant in SIRT3-knockout mice. This supports model-specific SIRT3 dependence, not proof of direct target binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Heart-weight/body-weight ratio after isoproterenolgenotype-dependent response Reduced with HKL in WT; ISO versus ISO+HKL not significant in SIRT3-KO; mean ± SE, n=5–8 mice; caption *P<0.05, ANOVA[3]
Cardiac interstitial fibrosis after isoproterenolgenotype-dependent response Reduced with HKL in WT; ISO versus ISO+HKL not significant in SIRT3-KO; mean ± SE, n=5 mice; caption *P<0.001, ANOVA[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
Co-treatment in a 7-day ISO model; exact honokiol initiation time not specified
Vehicle
Peanut oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type ISO plus honokiol
0.2 mg/kg/day honokiol
Same-genotype ISO-alone group; sham and honokiol-only groups also shownLower HW/BW ratio and fibrosis than ISO alone[3]
SIRT3-knockout ISO plus honokiol
0.2 mg/kg/day honokiol
Same-genotype ISO-alone group; sham and honokiol-only groups also shownNo significant improvement in HW/BW ratio or fibrosis versus ISO alone[3]
Wild-type ISO plus honokiol
Model: Adult wild-type mice
Reported limits: ISO-cohort strain/sex/age and exact HKL initiation time not assigned from TAC methods.
SIRT3-knockout ISO plus honokiol
Model: Adult sirt3-knockout mice
Reported limits: ISO-cohort strain/sex/age and exact HKL initiation time not assigned from TAC methods.
Methods and source locations

Compound reported in the paper: Honokiol; Compound label in the paper: HKL

Compound-level research findings only; tested material does not validate Adooq lots or clinical efficacy.

Results: HKL blocks induction of cardiac hypertrophy in SIRT3-dependent manner; Fig. 5A–C; Methods: Induction of hypertrophy in mice; Introduction chemical identity; Author Contributions: purified HKL supplied by M.B. and J.L.A.

Heart-weight/body-weight ratio after isoproterenol: Heart weight normalized to body weight — Fig. 5A and caption

Cardiac interstitial fibrosis after isoproterenol: Masson trichrome staining and fibrosis quantification — Fig. 5B,C and caption

Wild-type ISO plus honokiol · Fig. 5A–C; Methods: Induction of hypertrophy in mice

SIRT3-knockout ISO plus honokiol · Fig. 5A–C; Methods: Induction of hypertrophy in mice

Specifications

Manufacturer Adooq Bioscience
CAS Number 35354-74-6
Applications Antiangiogenic and Antitumor Agent
Formula C18H18O2
Molecular Weight 266.3
Synonyms houpa; hnk
SMILES
C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (195.24 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Po-Jen Chen, Yu-Ling Wang, Liang-Mou Kuo, et al. Honokiol suppresses TNF-α-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IκBα Scientific Reports (2016). PMID: 27212040 DOI: 10.1038/srep26554 Source material
  2. [2] Mikhail Alexeev, Denise K Grosenbaugh, David D Mott, et al. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABAA receptors Neuropharmacology (2012). PMID: 22445602 DOI: 10.1016/j.neuropharm.2012.03.002 Source material
  3. [3] Vinodkumar B Pillai, Sadhana Samant, Nagalingam R Sundaresan, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3 Nature Communications (2015). PMID: 25871545 DOI: 10.1038/ncomms7656 Source material

Added to your cart

View Cart Checkout
Loading...